Commentary on Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer

Affiliations

¹ Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom; Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. Electronic address: K.Spencer@leeds.ac.uk.
² The Royal Marsden NHS Foundation Trust, London, United Kingdom The Institute of Cancer Research, London, United Kingdom.

Editorial

Katie L Spencer et al. Int J Radiat Oncol Biol Phys. 2020.

. 2020 Nov 15;108(4):927-929.

doi: 10.1016/j.ijrobp.2020.08.021.

¹ Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom; Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. Electronic address: K.Spencer@leeds.ac.uk.
² The Royal Marsden NHS Foundation Trust, London, United Kingdom The Institute of Cancer Research, London, United Kingdom.

No abstract available

Comment on

Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Parikh NR, Chang EM, Nickols NG, Rettig MB, Raldow AC, Steinberg ML, Koontz BF, Vapiwala N, Deville C, Feng FY, Spratt DE, Reiter RE, Phillips R, Ost P, Tran PT, Kishan AU. Parikh NR, et al. Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):917-926. doi: 10.1016/j.ijrobp.2020.06.009. Epub 2020 Jun 13. Int J Radiat Oncol Biol Phys. 2020. PMID: 32544574 Free PMC article.